In reply: neoadjuvant TKI study in early- and intermediate stage hepatocellular carcinoma

Author(s):
Osanto, S.; Woei-A-Jin, F.J.S.H.; Coenraad, M.J.; Weijl, N.I.; Burgmans, M.C. (0000-0001-5258-291X); Burggraaf, J.
Published
2022
Publication type
Article / Letter to editor

Abstract

This letter to the editor responds to comments from Rizzo et al on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma.

Date issued
2022-10-21
Language
English
Publisher
OXFORD UNIV PRESS
Is part of
The Oncologist (2022), Vol. 27, no. 12, p. e977-e978
hdl
1887/3486068
doi
10.1093/oncolo/oyac215